New developments in pharmacological stress imaging

  • F. van Paul
  • Ernst E. van der Wall
  • Albert V. G. Bruschke
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 133)


Accurate assessment of the localization, extent and severity of jeopardized myocardium is invaluable for the management of patients with coronary artery disease. Moreover, identification of viable myocardium is of major importance when angioplasty or bypass-surgery is considered. Recent development of innovative imaging strategies provided the clinical cardiologist with new diagnostic tools to determine myocardial perfusion and left ventricular function. These imaging modalities require a (sub)maximal level of stress in order to increase coronary flow and myocardial oxygen demand. Although exercise is by far the most physiological method for producing a (sub)maximal level of stress, a considerable number of patients are unable to adequately perform conventional exercise stress testing. Pharmacological stress seems to be an appropriate substitute for bicycle and treadmill exercise, and is gaining increasing popularity. In addition, pharmacologically induced stress avoids excessive chest wall motion due to high respiration frequency, thereby contributing to high quality images. Currently, several stress agents are used in conjunction with thallium-201 scintigraphy, two-dimensional echocardiography and, recently, magnetic resonance imaging (MRI). The most employed agents include vasodilators such as dipyridamole and adenosine, and catecholamines such as dobutamine.


Coronary Artery Disease Myocardial Perfusion Imaging Coronary Flow Coronary Blood Flow Pharmacological Stress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albro PC, Gould KL, Ewstcott RJ, Hamilton GW, Ritchie JL, Williams DL. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic vasodilation. III. Clinical trial. Am J Cardiol 1978; 42: 751–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Leppo JA. Dipyridamole-thallium imaging: the lazy man’s stress test. J Nucl Med 1989; 30: 281–7.PubMedGoogle Scholar
  3. 3.
    Gould KL, Sorenson SG, Albro PC, Caldwell JH, Chaudhuri T, Hamilton GW. Thallium-201 myocardial imaging during coronary vasodilation induced by oral dipyridamole. J Nucl Med 1986; 27: 31–6.PubMedGoogle Scholar
  4. 4.
    Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW. Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction. N Engl J Med 1984; 310: 1014–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Leppo JA, Plaja J, Gionet M, Tumolo J, Paraskos JA, Cutler BS. Noninvasive evaluation of cardiac risk before elective vascular surgery. J Am Coll Cardiol 1987; 9: 269–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Boucher CA, Brewster DC, Darling RC, Okada RD, Strauss HW, Pohost GM. Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med 1985; 312: 389–94.CrossRefGoogle Scholar
  7. 7.
    Brown BG, Josephson MA, Petersen RB et al. Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease. Am J Cardiol 1981; 48: 1077–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Casale PN, Guiney TE, Strauss HW, Boucher CA. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988; 62: 799–802.PubMedCrossRefGoogle Scholar
  9. 9.
    Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 1978; 41: 267–78.PubMedCrossRefGoogle Scholar
  10. l0.
    FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247–57.PubMedCrossRefGoogle Scholar
  11. 11.
    Zeller FP, Blend MJ. The use of intravenous dipyridamole in thallium 201 myocardial perfusion imaging. Pharmacotherapy 1987; 7: 178–84.PubMedGoogle Scholar
  12. 12.
    Soloff LA, Gimenez JL, Winters WL Jr. Experimental and clinical observations on 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-pyrimidine(persantin). Am J Med Sci 1962; 243: 783–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Elliot EC. The effect of persantine on coronary flow and cardiac dynamics. Can Med Assoc J 1961; 85: 469–76.PubMedGoogle Scholar
  14. 14.
    Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Am J Cardiol 1974; 33: 87–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoffman JI. Maximal coronary flow and the concept of coronary vascular reserve. Circulation 1984; 70: 153–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Dole WP. Autoregulation of the coronary circulation. Prog Cardiovasc Dis 1987; 29:293–323.PubMedCrossRefGoogle Scholar
  17. 17.
    Gould KL, Westcott RJ, Albro PC, Hamilton GW. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. II. Clinical methodology and feasibility. Am J Cardiol 1978; 41: 279–87.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhu YY, Lee W, Botvinick E et al. The clinical and pathophysiologic implications of pain, ST abnormalities, and scintigraphic changes induced during dipyridamole infusion: their relationships to the peripheral hemodynamic response. Am Heart J 1988; 116: 1071–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Iskandrian AS, Heo J, Askenase A, Segal BL, Auerbach N. Dipyridamole cardiac imaging. Am Heart J 1988; 115: 432–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Beer SG, Heo J, Iskandrian AS. Dipyridamole thallium imaging. Am J Cardiol 1991; 67: 18D–26D.PubMedCrossRefGoogle Scholar
  21. 21.
    Gould KL. Quantification of coronary artery stenosis in vivo. Circ Res 1985; 57: 341–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Gould KL, Kelley KO, Bolson EL. Experimental validation of quantitative coronary arteriography for determining pressure-flow characteristics of coronary stenosis. Circulation 1982; 66: 930–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Gould KL, Kelley KO. Physiological significance of coronary flow velocity and changing stenosis geometry during coronary vasodilation in awake dogs. Circ Res 1982; 50: 695–704.PubMedCrossRefGoogle Scholar
  24. 24.
    Gould KL. Dynamic coronary stenosis. Am J Cardiol 1980; 45: 286–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Bache RJ, Schwartz JS. Effects of perfusion pressure distal to a coronary stenosis on transmural myocardial blood flow. Circulation 1982; 65: 928–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Hoffman JI. Determinants and prediction of transmural myocardial perfusion. Circulation 1978; 58: 381–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Meerdink DJ, Okada RD, Leppo JA. The effect of dipyridamole on transmural blood flow gradients. Chest 1989; 96: 400–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Gould KL. Assessing coronary stenosis severity-a recurrent clinical need (editorial). J Am Coll Cardiol 1986; 8: 91–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Braunwald E, Sobel BE. Coronary blood flow and myocardial ischemia. In: Braunwald E, editor. Heart disease, a textbook of cardiovascular medicine. Philadelphia: Saunders, 1984: 1235–62.Google Scholar
  30. 29.
    Gould KL. Coronary steal; Is it clinically important? (editorial). Chest 1989; 96: 227–9.PubMedCrossRefGoogle Scholar
  31. 30.
    Ranhosky A, Kempthorne-Rawson J, and the Intravenous Dipyridamole-Thallium Imaging Study Group. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation 1990; 81: 1205–9.PubMedCrossRefGoogle Scholar
  32. 31.
    Alfonso S. Inhibition of coronary vasodilating action of dipyridamole and adenosine by aminophylline in the dog. Circ Res 1970; 26: 743–52.CrossRefGoogle Scholar
  33. 32.
    Fredholm BB, Persson CG. Xanthine derivatives as adenosine receptor antagonists. Eur J Pharmacol 1982; 81: 673–6.PubMedCrossRefGoogle Scholar
  34. 33.
    Picano E, Distante A, Masini M, Morales MA, Lattanzi F, L’Abbate A. Dipyridamoleechocardiography test in effort angina pectoris. Am J Cardiol 1985; 56: 452–6.PubMedCrossRefGoogle Scholar
  35. 34.
    Margonato A, Chierchia S, Cianflone D et al. Limitations of dipyridamole-echocardiography in effort angina pectoris. Am J Cardiol 1987; 59: 225–30.PubMedCrossRefGoogle Scholar
  36. 35.
    Picano E, Lattanzi F, Masini M, Distante A, L’Abbate A. High dose dipyridamole echocardiography test in effort angina pectoris. J Am Coll Cardiol 1986; 8: 848–54.PubMedCrossRefGoogle Scholar
  37. 36.
    Picano E. Dipyridamole-echocardiography test: historical background and physiologic basis. Eur Heart J 1989; 10: 365–76.PubMedGoogle Scholar
  38. 37.
    Robertson WS, Feigenbaum H, Armstrong WF, Dillon JC, O’Donnel J, McHenry PW. Exercise echocardiography: a clinically practical addition in the evaluation of coronary artery disease. J Am Coll Cardiol 1983; 2: 1085–91.PubMedCrossRefGoogle Scholar
  39. 38.
    Ryan T, Vasey CG, Presti CF, O’Donnel JA, Feigenbaum H, Armstrong WF. Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest. J Am Coll Cardiol 1988; 11: 993–9.PubMedCrossRefGoogle Scholar
  40. 39.
    Picano E, Morales MA, Distante A et al. Dipyridamole echocardiography test in angina at rest: noninvasive assessment of coronary stenosis underlying spasm. Am Heart J 1986; 111: 688–91.PubMedCrossRefGoogle Scholar
  41. 40.
    Picano E, Lattanzi F, Masini M, Distante A, L’Abbate A. Comparison of the high-dose dipyridamole-echocardiography test and exercise two-dimensional echocardiography for diagnosis of coronary artery disease. Am J Cardiol 1987; 59: 539–42.PubMedCrossRefGoogle Scholar
  42. 41.
    Bolognese L, Sarasso G, Aralda D, Bongo AS, Rossi L, Rossi P. High dose dipyridamole echocardiography early after uncomplicated acute myocardial infarction: correlation with exercise testing and coronary angiography. J Am Coll Cardiol 1989; 14: 357–63.PubMedCrossRefGoogle Scholar
  43. 42.
    Pirelli S, Danzi GB, Alberti A et al. Comparison of usefulness of high-dose dipyridamole echocardiography and exercise electrocardiography for detection of asymptomatic restenosis after coronary angioplasty. Am J Cardiol 1991; 67: 1335–8.PubMedCrossRefGoogle Scholar
  44. 43.
    Masini M, Picano E, Lattanzi F, Distante A, L’Abbate A. High dose dipyridamole-echocardiography test in women: correlation with exercise-electrocardiography test and coronary arteriography. J Am Coll Cardiol 1988; 12: 682–5.PubMedCrossRefGoogle Scholar
  45. 44.
    Picano E, Severi S, Michelassi C et al. Prognostic importance of dipyridamole-echocardiography test in coronary artery disease. Circulation 1989; 80: 450–7.PubMedCrossRefGoogle Scholar
  46. 45.
    Picano E, Pirelli S, Marzilli M et al. Usefulness of high-dose dipyridamole-echocardiography test in coronary angioplasty. Circulation 1989; 80: 807–15.PubMedCrossRefGoogle Scholar
  47. 46.
    Higgins CB. Malcolm Hanson memorial lecture. MR of the heart: anatomy, physiology and metabolism. Am J Roentgenol 1988; 151: 239–48.Google Scholar
  48. 47.
    Haase A, Frahm J, Matthaei D, Hänicke W, Merboldt KD. FLASH imaging. Rapid NMR imaging using low flip-angle pulses. J Magn Reson 1986; 67: 258–66.CrossRefGoogle Scholar
  49. 48.
    Higgins CB, Holt W, Pflugfelder P, Sechtem U. Functional evaluation of the heart with MRI. Magn Reson Med 1988; 6: 121–39.PubMedCrossRefGoogle Scholar
  50. 49.
    Pettigrew R. Dynamic cardiac MR imaging. Techniques and applications. Radiol Clin North Am 1989; 27: 1183–203.PubMedGoogle Scholar
  51. 50.
    Sechtem U, Pflugfelder PW, Gould RG, Cassidy MM, Higgins CB. Measurement of right and left ventricular volumes in healthy individuals with cine MR imaging. Radiology 1987; 163: 697–702.Google Scholar
  52. 51.
    Utz JA, Herfkens RJ, Heinsimer JA et al. Cine MR determination of left ventricular ejection fraction. Am J Roentgenol 1987; 148: 839–43.Google Scholar
  53. 52.
    Buser PT, Aufferman W, Holt WW et al. Noninvasive evaluation of global left ventricular function with use of cine nuclear magnetic resonance. J Am Coll Cardiol 1989; 13:1294–300.PubMedCrossRefGoogle Scholar
  54. 53.
    Sechtem U, Sommerhoff BA, Markiewicz W, White RD, Cheitlin MD, Higgins CB. Regional left ventricular wall thickening by magnetic resonance imaging: evaluation in normal persons and patients with global and regional dysfunction. Am J Cardiol 1987; 59: 145–51.PubMedCrossRefGoogle Scholar
  55. 54.
    Peshock RM, Rokey R, Malloy CM et al. Assessment of myocardial systolic wall thickening using nuclear magnetic resonance imaging. J Am Coll Cardiol 1989; 14: 653–9.PubMedCrossRefGoogle Scholar
  56. 55.
    Lotan CS, Cranney GB, Bouchard A, Bittner V, Pohost GM. The value of cine nuclear magnetic resonance imaging for assessing regional ventricular function. J Am Coll Cardiol 1989; 14: 1721–9.PubMedCrossRefGoogle Scholar
  57. 56.
    Auffermann W, Wagner S, Holt WW et al. Noninvasive determination of left ventricular output and wall stress in volume overload and in myocardial disease by cine magnetic resonance imaging. Am Heart J 1991; 121: 1750–8.PubMedCrossRefGoogle Scholar
  58. 57.
    Sechtem U, Pflugfelder PW, Cassidy MM et al. Mitral or aortic régurgitation: quantification of régurgitant volumes in patients with cine MR imaging. Radiology 1988; 167: 425–30.PubMedGoogle Scholar
  59. 58.
    Pennell DJ, Underwood SR, Longmore DB. Detection of coronary artery disease using MR imaging with dipyridamole infusion. J Comput Assist Tomogr 1990; 14: 167–70.PubMedCrossRefGoogle Scholar
  60. 59.
    Pennell DJ, Underwood SR. Stress magnetic resonance imaging in coronary artery disease. In: Van der Wall EE, De Roos A, editors. Magnetic resonance in coronary artery disease. Dordrecht: Kluwer, 1990: 217–39.Google Scholar
  61. 60.
    Wackers FJ. Pharmacologic stress with dipyridamole: how lazy can one be? [editorial]. J Nucl Med 1990; 31: 102–7.Google Scholar
  62. 6l.
    Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32: 73–97.PubMedCrossRefGoogle Scholar
  63. 62.
    Verani MS, Mahmarian JJ, Hixson JB, Boyce TM, Staudacher RA. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990; 82: 80–7.PubMedCrossRefGoogle Scholar
  64. 63.
    Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82: 1595–606.PubMedCrossRefGoogle Scholar
  65. 64.
    Sylven C, Beermann B, Jonzon B, Brandt R. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J 1986; 293: 227–30.CrossRefGoogle Scholar
  66. 65.
    Crea F, Pupita G, Galassi AR et al. Role of adenosine in pathogenesis of anginal pain. Circulation 1990; 81: 164–72.PubMedCrossRefGoogle Scholar
  67. 66.
    DiMarco JP, Sellers TD, Berne RM, West GA, Belardinelli L. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68: 1254–63.PubMedCrossRefGoogle Scholar
  68. 67.
    DiMarco JP, Sellers TD, Lerman BB, Greenberg ML, Berne RM, Belardinelli L. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 1985; 6: 417–25.PubMedCrossRefGoogle Scholar
  69. 68.
    Bardenheuer H, Whelton B, Sparks HV Jr. Adenosine release by isolated guinea pig heart in response to isoproterenol, acetylcholine and acidosis: the minimal role of vascular endothelium. Circ Res 1987; 61: 594–600.PubMedCrossRefGoogle Scholar
  70. 69.
    Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980; 47: 807–13.PubMedCrossRefGoogle Scholar
  71. 70.
    Triner L, Nahas GG, Vulliemoz Y et al. Cyclic AMP and smooth muscle functions. Ann N Y Acad Sci 1971; 185: 458–76.PubMedCrossRefGoogle Scholar
  72. 71.
    Kurtz A. Adenosine stimulates guanylate cyclase activity in vascular smooth muscle cells. J Biol Chem 1987; 262: 6296–300.PubMedGoogle Scholar
  73. 72.
    Long CJ, Stone TW. Adenosine produces agonist-induced production of inositol phosphatase in rat aorta. J Pharm Pharmacol 1987; 39: 1010–4.PubMedCrossRefGoogle Scholar
  74. 73.
    Fenton RA, Bruttig SP, Rubio R, Berne RM. Effect of adenosine on calcium uptake by intact and cultured vascular smooth muscle. Am J Physiol 1987; 252: H797–H804.Google Scholar
  75. 74.
    Lokhandwala MF. Inhibition of cardiac sympathetic neurotransmission by adenosine. Eur J Pharmacol 1979; 60: 353–7.PubMedCrossRefGoogle Scholar
  76. 75.
    Wakade AR, Wakade TD. Inhibition of noradrenaline release by adenosine. J Physiol 1978; 282: 35–49.PubMedGoogle Scholar
  77. 76.
    Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250: H1145–9.Google Scholar
  78. 77.
    Favale S, Di Biase M, Rizzo U, Belardinelli L, Rizzon P. Effect of adenosine and adenosine-5′-triphosphate on atrioventricular conduction in patients. J Am Coll Cardiol 1985; 5: 1212–9.PubMedCrossRefGoogle Scholar
  79. 78.
    Clemo HF, Belardinelli L. Effect of adenosine on atrioventricular conduction. I. Site and characterization of adenosine action in the guinea pig atrioventricular node. Circ Res 1986; 59: 427–36.Google Scholar
  80. 79.
    Dobson JG Jr. Mechanism of adenosine inhibition of catecholamine-induced responses in heart. Circ Res 1983; 52: 151–60.PubMedCrossRefGoogle Scholar
  81. 80.
    Dobson JG Jr. Adenosine reduces catecholamine contractile responses in oxygenated and hypoxic atria. Am J Physiol 1983; 245: H468–74.Google Scholar
  82. 81.
    Baumann G, Schrader J, Gerlach E. Inhibitory action of adenosine on histamine-and dopamine-stimulated cardiac contractility and adenylate cyclase in guinea pigs. Circ Res 1981; 48: 259–66.PubMedCrossRefGoogle Scholar
  83. 82.
    West GA, Isenberg G, Belardinelli L. Antagonism of forskolin effects by adenosine in isolated hearts and ventricular myocytes. Am J Physiol 1986; 250: H769–77.Google Scholar
  84. 83.
    Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res 1987; 61: 779–86.PubMedCrossRefGoogle Scholar
  85. 84.
    Nguyen T, Heo J, Ogilby JD, Iskandrian AS. Single photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia: correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography. J Am Coll Cardiol 1990; 16: 1375–83.PubMedCrossRefGoogle Scholar
  86. 85.
    Coyne EP, Belvedere DA, Van de Streek PR, Weiland FL, Evans RB, Spaccavento LJ. Thallium-201 scintigraphy after intravenous infusion of adenosine compared with exercise thallium testing in the diagnosis of coronary artery disease. J Am Coll Cardiol 1991; 17: 1289–94.PubMedCrossRefGoogle Scholar
  87. 86.
    Iskandrian AS, Heo J, Nguyen T et al. Assessment of coronary artery disease using singlephoton emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1991; 67: 1190–4.PubMedCrossRefGoogle Scholar
  88. 87.
    Zoghbi WA. Use of adenosine echocardiography for diagnosis of coronary artery disease. Am Heart J 1991; 122: 285–92.PubMedCrossRefGoogle Scholar
  89. 88.
    Vasu MA, O’Keefe DD, Kapellakis GZ et al. Myocardial oxygen consumption: effects of epinephrine, isoproterenol, dopamine, norepinephrine and dobutamine. Am J Physiol 1978; 235: H237–41.Google Scholar
  90. 89.
    Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure. Circulation 1977; 56: 468–72.PubMedCrossRefGoogle Scholar
  91. 90.
    Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466–75.PubMedCrossRefGoogle Scholar
  92. 91.
    Stoner JD III, Bolen JL, Harrison DC. Comparison of dobutamine and dopamine in treatment of severe heart failure. Br Heart J 1977; 39: 536–9.PubMedCrossRefGoogle Scholar
  93. 92.
    Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 1979; 300: 17–22.PubMedCrossRefGoogle Scholar
  94. 93.
    Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci 1987; 294: 244–8.PubMedCrossRefGoogle Scholar
  95. 94.
    Vatner SF, Higgins CB, Braunwald E. Effects of norepinephrine on coronary circulation and left ventricular dynamics in the conscious dog. Circ Res 1974; 34: 812–23.PubMedCrossRefGoogle Scholar
  96. 95.
    Goldberg LI, Hsieh YY, Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 1977; 19: 327–40.PubMedCrossRefGoogle Scholar
  97. 96.
    Higgins CB, Millard RW, Braunwald E, Vatner SF. Effects and mechanisms of action of dopamine on regional hemodynamics in the conscious dog. Am J Physiol 1973; 225: 432–43.PubMedGoogle Scholar
  98. 97.
    Gunnar RM, Loeb HS, Pietras RJ, Tobin JR Jr. Ineffectiveness of isoproterenol in shock due to acute myocardial infarction. JAMA 1967; 202: 1124–8.CrossRefGoogle Scholar
  99. 98.
    Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185–96.PubMedCrossRefGoogle Scholar
  100. 99.
    Ruffolo RR Jr, Yaden EL. Vascular effects of the stereoisomers of dobutamine. J Pharmacol ExpTher 1983; 224: 46–50.Google Scholar
  101. l00.
    Ruffolo RR Jr, Spradlin TA, Pollock GD, Waddell JE, Murphy PJ. a-and β-adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1981; 219: 447–52.PubMedGoogle Scholar
  102. 101.
    Leier CV, Unverferth DV. Dobutamine. Ann Intern Med 1983; 99: 490–6.PubMedGoogle Scholar
  103. 102.
    Robie NW, Nutter DO, Moody C, McNay JL. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res 1974; 34: 663–71.PubMedCrossRefGoogle Scholar
  104. 103.
    Bianchi C, Diaz R, Gonzales C, Beregovich J. Effects of dobutamine on atrioventricular conduction. Am Heart J 1975; 90: 474–8.PubMedCrossRefGoogle Scholar
  105. 104.
    Loeb HS, Sinno MZ, Saudye AL, Towne WD, Gunnar RM. Electrophysiologic properties of dobutamine. Circ Shock 1974; 1: 217–20.Google Scholar
  106. 105.
    Leier CV, Unverferth DV, Kates RE. The relationship between plasma dobutamine concentrations and cardiovascular réponses in cardiac failure. Am J Med 1979; 66: 238–42.PubMedCrossRefGoogle Scholar
  107. 106.
    Kates RE, Leier CV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978; 24: 537–41.PubMedGoogle Scholar
  108. 107.
    Murphy PJ, Williams TL, Kau DL. Disposition of dobutamine in the dog. J Pharmacol Exp Ther 1976; 199: 423–31.PubMedGoogle Scholar
  109. 108.
    Unverferth DV, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 1980; 69: 262–9.PubMedCrossRefGoogle Scholar
  110. 109.
    Maroko PR, Kjekshus JK, Sobel BE et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67–82.PubMedCrossRefGoogle Scholar
  111. 110.
    Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588–94.PubMedCrossRefGoogle Scholar
  112. 111.
    Willerson JT, Hutton I, Watson JT, Platt MR, Templeton GH. Influence of dobutamine on regional myocardial blood flow and ventricular performance during acute and chronic myocardial ischemia in dogs. Circulation 1976; 53: 828–33.PubMedCrossRefGoogle Scholar
  113. 112.
    Vatner SF, Baig H. Importance of heart rate in determining the effects of sympathomimetic amines on regional myocardial function and blood flow in conscious dogs with acute myocardial ischemia. Circ Res 1979; 45: 793–803.PubMedCrossRefGoogle Scholar
  114. 113.
    Meyer SL, Curry GC, Donsky MS, Twieg DB, Parkey RW, Willerson JT. Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease. Am J Cardiol 1976; 38: 103–8.PubMedCrossRefGoogle Scholar
  115. 114.
    McGillem MJ, DeBoe SF, Friedman HZ, Mancini GB. The effects of dopamine and dobutamine on regional function in the presence of rigid coronary stenoses and subcritical impairments of reactive hyperemia. Am Heart J 1988; 115: 970–7.CrossRefGoogle Scholar
  116. 115.
    Tuttle RR, Pollack GD, Todd G, MacDonald B, Tust R, Dusenberry W. The effect of dobutamine on cardiac oxygen balance, regional blood flow, and infarction severity after coronary artery narrowing in dogs. Circ Res 1977; 41: 357–64.PubMedCrossRefGoogle Scholar
  117. 116.
    Palac RT, Coombs BJ, Kudenchuk PJ, Crane SK, Murphy ES. Two dimensional echocardiography during dobutamine infusion: comparison with exercise testing in evaluation of coronary disease [abstract]. Circulation 1984; 70 (suppl II): II184.Google Scholar
  118. 117.
    Berthe C, Pierard LA, Hiernaux M et al. Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dobutamine infusion. Am J Cardiol 1986; 58: 1167–72.PubMedCrossRefGoogle Scholar
  119. 118.
    Mannering D, Cripps T, Leech G et al. The dobutamine test as an alternative to exercise testing after acute myocardial infarction. Br Heart J 1988; 59: 521–6.PubMedCrossRefGoogle Scholar
  120. 119.
    Cohen JL, Greene TO, Ottenweller J, Binenbaum SZ, Wilchfort SD, Kim CS. Dobutamine digital echocardiography for detecting coronary artery disease. Am J Cardiol 1991; 67: 1311–8.PubMedCrossRefGoogle Scholar
  121. 120.
    Previtali M, Lanzarini L, Ferrario M, Tortorici M, Mussini A, Montemartini C. Dobutamine versus dipyridamole echocardiography in coronary artery disease. Circulation 1991; 83 (suppl III): 11127–31.Google Scholar
  122. 121.
    Sawada SG, Segar DS, Ryan T et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. Circulation 1991; 83: 1605–14.PubMedCrossRefGoogle Scholar
  123. 122.
    Fung AY, Gallagher KP, Buda AJ. The physiologic basis of dobutamine as compared with dipyridamole stress interventions in the assessment of critical coronary stenosis. Circulation 1987; 76: 943–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • F. van Paul
  • Ernst E. van der Wall
  • Albert V. G. Bruschke

There are no affiliations available

Personalised recommendations